We conducted a systematic review of randomized clinical trials evaluating the effects of aerobic, resistance and/or combined training on flow-mediated dilation (FMD) and/or pulse wave velocity (PWV) in older adults. The studies were selected from the electronic databases PubMed, Cochrane, LILACS, EMBASE, Web of Science, and the gray literature. We assessed the studies using Cochrane risk of bias (RoB2) tool and the GRADE tool. The GRADE assessment showed moderate quality of evidence for aerobic training and resistance training and very low for combined training. The measures of effects are presented as mean differences of the intervention group versus the control group and related 95% confidence intervals (95% CIs) pooled by a random-effects model using an inverse variance method. Our analysis of 24 RCTs (Intervention group [n = 251]: 67.7 ± 5.6 years old; control group [n = 228]: 68.7 ± 5.9 years old) showed that aerobic training was effective to improve FMD (0.64% [95% CI 0.24 to 1.03], p = 0.002) and PWV (–1.21 m/s [95% CI –1.37 to –1.05], p< 0.001) by compared to the control group. The subgroup analyses showed no FMD differences following aerobic training in healthy adults when compared to those with any health condition. Combined training was effective in improving FMD (0.60% [95% CI 0.50 to 0.71], p< 0.001) and PWV (-0.79 m/s [95% CI –1.23 to –0.35], p = 0.002). But these same parameters did not show any improvement in response to resistance training. A major limitation of this study is that the analysis to evaluate the effect of resistance training on PWV include only one study, and no inferences could be made from the data. Aerobic and combined training, but not resistant training, improve flow-mediated dilation and pulse wave velocity in the elderly. PROSPERO: CRD42021275282.

Background: We conducted a systematic review and meta-analysis to examine the effect of dietary intake of cocoa on anthropometric measurements, lipid and glycemic profiles, and blood pressure levels in adults, with and without comorbidities. Methods: The databases used were MEDLINE (PubMed), EMBASE, Web of Science, Cochrane, LILACS, and SciELO. The eligible studies were randomized clinical trials (RCTs) involving adults undergoing cocoa consumption (cocoa extract or ≥70% cocoa dark chocolate) for ≥4 weeks that evaluated at least one of the following markers: body weight, body mass index (BMI), waist/abdominal circumference, total cholesterol, LDL-c, triglycerides, HDL-c, blood glucose, glycated hemoglobin (HbA1c), and systolic and diastolic blood pressure (SBP/DBP). Results: Thirty-one studies were included, totaling 1986 participants. Cocoa consumption showed no effects on body weight, BMI, waist circumference, triglycerides, HDL-c and HbA1c. Yet, there was a reduction in total cholesterol (−8.35 mg/dL, 95% CI −14.01; −2.69 mg/dL), LDL-c (−9.47 mg/dL, 95% CI −13.75; −5.20 mg/dL), fasting blood glucose (−4.91 mg/dL, 95% CI −8.29; −1.52 mg/dL), SBP (−2.52 mmHg, 95% CI −4.17; −0.88 mmHg), and DBP (−1.58 mmHg, 95% CI −2.54; −0.62 mmHg). Conclusions: The consumption of cocoa showed protective effects on major cardiometabolic risk markers that have a clinical impact in terms of cardiovascular risk reduction.

Background: Cardiometabolic diseases cover a spectrum of interrelated conditions linked to metabolic dysfunctions and/or cardiovascular disorders, including systemic arterial hypertension, diabetes mellitus, dyslipidemia, and obesity. Cocoa is a rich source of dietary polyphenols and has been associated with cardiovascular health benefits. However, beneficial effects of cocoa consumption and appropriate quantities in decreasing cardiometabolic risk factors have yet to be established. Therefore, we will conduct a systematic review and meta-analysis to examine the effects of cocoa consumption on cardiometabolic risk markers (total cholesterol, HDL, LDL, triglycerides, blood glucose, glycated hemoglobin, waist circumference, abdominal circumference, body mass index, systolic blood pressure and diastolic blood pressure) in adults with or without established cardiovascular risk factors. Methods: Our review will include all randomized controlled trials published in English, Portuguese and Spanish with no date of publication restrictions evaluating the effects of cocoa consumption on cardiometabolic risk markers selected from the databases MEDLINE (PubMed), LILACS, Cochrane, EMBASE, Web of Science and SciELO, and gray literature. Eligible studies must involve adults (age ≥18y), and the consumption of cocoa or dark chocolate (≥ 70% cocoa), include a control group and evaluate blood pressure, anthropometric measurements, and lipid or glycemic profiles. We will use risk-of-bias 2 (RoB2) tool to assess the risk of bias and the GRADE system to assess the strength of evidence. Statistical analyses will be performed using RStudio for Windows and R package meta. Discussion: This meta-analysis will summarize existing evidence on the effects of cocoa consumption on cardiometabolic health in adults. Better understanding the effects of cocoa consumption on anthropometric measurements, blood pressure, and lipid and glycemic profiles can provide valuable insights for health professionals to improve dietary recommendations regarding appropriate quantities. Trial registration: Systematic Review Registration: PROSPERO CRD42023484490.